Understand the source comparison
Research Applications: When to Choose SS-31 vs SS-LUP-332
SS-31 demonstrates efficacy in ischaemia-reperfusion models where mitochondrial damage occurs within minutes to hours. Myocardial infarction, stroke, transplant organ preservation, acute kidney injury. The EMBRACE STEMI trial (2020) administered SS-31 intraven
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-31 demonstrates efficacy in ischaemia-reperfusion models where mitochondrial damage occurs within minutes to hours. Myocardial infarction, stroke, transplant organ preservation, acute kidney injury. The EMBRACE STEMI trial (2020) administered SS-31 intravenously during primary percutaneous coronary intervention for ST-elevation myocardial infarction; while the peptide reduced infarct size by 17% on cardiac MRI at 4 days (p=0.026), this didn't translate to improved left ventricular function at 12 weeks, and the trial missed its primary endpoint. The mechanism worked. Cardiolipin was protected, ROS emission decreased. But mitochondrial rescue alone wasn't sufficient to override the complex post-infarction remodelling process involving inflammation, fibrosis, and neurohumoral activation.
- SS-LUP-332 shows promise in metabolic reprogramming contexts where increasing oxidative capacity benefits the phenotype. Exercise adaptation models, obesity-related insulin resistance, cachexia, and age-related sarcopenia. A 2023 preclinical study in Cell Metabolism demonstrated that SS-LUP-332 improved endurance running time by 43% in sedentary mice after 14 days of administration, with corresponding increases in cytochrome c oxidase activity, mitochondrial respiration rates, and type IIA fibre proportion. The compound essentially mimicked aspects of endurance training at the molecular level. However, when tested in models of acute mitochondrial toxicity (rotenone exposure, antimycin A inhibition), SS-LUP-332 provided no protection. It can't rescue failing mitochondria, only build new capacity in metabolically responsive tissue.
- Our experience with research teams shows the most common misapplication: using SS-31 in chronic metabolic disease models where mitochondrial quantity (not quality under stress) is the limiting factor, or using SS-LUP-332 in acute injury models where transcriptional lag time renders the intervention too slow. If the experimental timeline is hours to days and the injury is oxidative. SS-31. If the timeline is weeks and the goal is metabolic adaptation. SS-LUP-332. The peptides aren't competing solutions; they address different biological bottlenecks.